

Nathalie Bardin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7119242/publications.pdf>

Version: 2024-02-01

84
papers

2,565
citations

201385

27
h-index

205818

48
g-index

88
all docs

88
docs citations

88
times ranked

3260
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. <i>Blood</i> , 2001, 98, 3677-3684.	0.6	268
2	Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2004, 91, 667-673.	1.8	218
3	Outside-in Signaling Pathway Linked to CD146 Engagement in Human Endothelial Cells. <i>Journal of Biological Chemistry</i> , 2001, 276, 1564-1569.	1.6	117
4	CD146 and its Soluble Form Regulate Monocyte Transendothelial Migration. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 746-753.	1.1	110
5	Soluble CD146, a novel endothelial marker, is increased in physiopathological settings linked to endothelial junctional alteration. <i>Thrombosis and Haemostasis</i> , 2003, 90, 915-920.	1.8	94
6	Activation of Human Endothelial Cells via S-Endo-1 Antigen (CD146) Stimulates the Tyrosine Phosphorylation of Focal Adhesion Kinase p125FAK. <i>Journal of Biological Chemistry</i> , 1998, 273, 26852-26856.	1.6	91
7	Clinical Features and Complications of <i>Coxiella burnetii</i> Infections From the French National Reference Center for Q Fever. <i>JAMA Network Open</i> , 2018, 1, e181580.	2.8	77
8	Soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. <i>Blood</i> , 2010, 115, 3843-3851.	0.6	75
9	Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. <i>Inflammatory Bowel Diseases</i> , 2006, 12, 16-21.	0.9	68
10	Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. <i>Medicine (United States)</i> , 2016, 95, e3748.	0.4	64
11	Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity. <i>Arthritis and Rheumatology</i> , 2020, 72, 1953-1955.	2.9	64
12	Role of reactive oxygen species and p38 MAPK in the induction of the pro-adhesive endothelial state mediated by IgG from patients with anti-phospholipid syndrome. <i>International Immunology</i> , 2005, 17, 489-500.	1.8	62
13	CD146 Short Isoform Increases the Proangiogenic Potential of Endothelial Progenitor Cells In Vitro and In Vivo. <i>Circulation Research</i> , 2010, 107, 66-75.	2.0	62
14	Rickettsia conorii Infection Enhances Vascular Cell Adhesion Molecule-1 and Intercellular Adhesion Molecule-1-Dependent Mononuclear Cell Adherence to Endothelial Cells. <i>Journal of Infectious Diseases</i> , 1997, 175, 1142-1152.	1.9	55
15	CD146 (Cluster of Differentiation 146). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1026-1033.	1.1	54
16	CD146 mediates VEGF-induced melanoma cell extravasation through FAK activation. <i>International Journal of Cancer</i> , 2015, 137, 50-60.	2.3	45
17	Mouse CD146/MCAM is a marker of natural killer cell maturation. <i>European Journal of Immunology</i> , 2008, 38, 2855-2864.	1.6	44
18	Correlation of Clinicoserologic and Pathologic Classifications of Inflammatory Myopathies. <i>Medicine (United States)</i> , 2013, 92, 15-24.	0.4	42

#	ARTICLE	IF	CITATIONS
19	Soluble Melanoma Cell Adhesion Molecule (sMCAM/sCD146) Promotes Angiogenic Effects on Endothelial Progenitor Cells through Angiomotin. <i>Journal of Biological Chemistry</i> , 2013, 288, 8991-9000.	1.6	41
20	Immunoglobulin G Anticardiolipin Antibodies and Progression to Q Fever Endocarditis. <i>Clinical Infectious Diseases</i> , 2013, 57, 57-64.	2.9	38
21	Evaluation of the BioPlex 2200 ANA Screen for the Detection of Antinuclear Antibodies and Comparison with Conventional Methods. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 245-255.	1.8	35
22	Antiphospholipid Antibody Syndrome With Valvular Vegetations in Acute Q Fever. <i>Clinical Infectious Diseases</i> , 2016, 62, 537-544.	2.9	33
23	Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis?. <i>Immunobiology</i> , 2007, 212, 557-565.	0.8	32
24	Prevalence of Autoantibodies to Cyclic Citrullinated Peptide in Patients with Rheumatic Diseases other than Rheumatoid Arthritis: A French Multicenter Study. <i>Clinical Reviews in Allergy and Immunology</i> , 2008, 34, 40-44.	2.9	30
25	Contribution of anti-Î²2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. <i>Rheumatology</i> , 2014, 53, 1215-1218.	0.9	30
26	Soluble CD146 boosts therapeutic effect of endothelial progenitors through proteolytic processing of short CD146 isoform. <i>Cardiovascular Research</i> , 2016, 111, 240-251.	1.8	29
27	Heterogeneous clinical spectrum of anti-SRP myositis and importance of the methods of detection of anti-SRP autoantibodies: a multicentric study. <i>Immunologic Research</i> , 2016, 64, 677-686.	1.3	29
28	Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease. <i>Rheumatology International</i> , 2018, 38, 813-819.	1.5	29
29	BioPlexâ„¢ 2200 multiplexed system: Simultaneous detection of anti-dsDNA and anti-chromatin antibodies in patients with systemic lupus erythematosus. <i>Autoimmunity</i> , 2009, 42, 63-68.	1.2	28
30	Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. <i>International Journal of Infectious Diseases</i> , 2021, 113, 23-25.	1.5	28
31	Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics. <i>PLoS ONE</i> , 2015, 10, e0134218.	1.1	27
32	Normal and Pathological Placental Angiogenesis. <i>BioMed Research International</i> , 2015, 2015, 1-2.	0.9	25
33	Role of CD146 (MCAM) in Physiological and Pathological Angiogenesisâ€”Contribution of New Antibodies for Therapy. <i>Biomedicines</i> , 2020, 8, 633.	1.4	25
34	Antiphospholipid Antibodies in Women Undergoing In Vitro Fertilization Treatment: Clinical Value of IgA Anti-Î²2glycoprotein I Antibodies Determination. <i>BioMed Research International</i> , 2014, 2014, 1-5.	0.9	24
35	Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2016, 11, e0160879.	1.1	24
36	Seasonal variations of systemic lupus erythematosus flares in southern France. <i>European Journal of Internal Medicine</i> , 2012, 23, 250-254.	1.0	22

#	ARTICLE	IF	CITATIONS
37	Increased serum levels of fractalkine and mobilisation of CD34+CD45 ⁺ endothelial progenitor cells in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2017, 19, 60.	1.6	22
38	Original Approach for Automated Quantification of Antinuclear Autoantibodies by Indirect Immunofluorescence. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	20
39	Thrombosis and antiphospholipid antibody syndrome during acute Q fever. <i>Medicine (United States)</i> , 2017, 96, e7578.	0.4	19
40	Identification of soluble CD146 as a regulator of trophoblast migration: potential role in placental vascular development. <i>Angiogenesis</i> , 2013, 16, 329-342.	3.7	18
41	Identification of CD146 as a novel molecular actor involved in systemic sclerosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1448-1451.e6.	1.5	18
42	TH17 cells expressing CD146 are significantly increased in patients with Systemic sclerosis. <i>Scientific Reports</i> , 2019, 9, 17721.	1.6	18
43	Tubular CD146 Expression in Nephropathies Is Related to Chronic Renal Failure. <i>Nephron Experimental Nephrology</i> , 2005, 99, e105-e111.	2.4	17
44	New treatment options for lupus – a focus on belimumab. <i>Therapeutics and Clinical Risk Management</i> , 2012, 8, 33.	0.9	17
45	A novel anti-CD146 antibody specifically targets cancer cells by internalizing the molecule. <i>Oncotarget</i> , 2017, 8, 112283-112296.	0.8	16
46	Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma. <i>Theranostics</i> , 2018, 8, 2447-2458.	4.6	16
47	Therapeutic and Diagnostic Antibodies to CD146: Thirty Years of Research on Its Potential for Detection and Treatment of Tumors. <i>Antibodies</i> , 2017, 6, 17.	1.2	15
48	Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2 γ dephosphorylation by the GADD34/PP1c complex. <i>Science Signaling</i> , 2018, 11, .	1.6	15
49	Heterogeneity of anti- β 2-glycoprotein I antibodies. <i>Thrombosis and Haemostasis</i> , 2005, 93, 80-87.	1.8	14
50	Autoantibodies Targeting Ficolin-2 in Systemic Lupus Erythematosus Patients With Active Nephritis. <i>Arthritis Care and Research</i> , 2018, 70, 1263-1268.	1.5	14
51	The first assessment of soluble CD146 in women with unexplained pregnancy loss. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1280-1284.	1.8	14
52	Therapeutic targeting of soluble CD146/MCAM with the M2 μ 1 monoclonal antibody prevents metastasis development and procoagulant activity in CD146 α -positive invasive tumors. <i>International Journal of Cancer</i> , 2020, 147, 1666-1679.	2.3	13
53	CD146/sCD146 in the Pathogenesis and Monitoring of Angiogenic and Inflammatory Diseases. <i>Biomedicines</i> , 2020, 8, 592.	1.4	12
54	Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population. <i>European Journal of Internal Medicine</i> , 2010, 21, 114-117.	1.0	11

#	ARTICLE	IF	CITATIONS
55	Association between anti-C1q antibodies and glomerular tuft necrosis in lupus nephritis. <i>Clinical Nephrology</i> , 2012, 77, 211-218.	0.4	11
56	Prevalence of autoantibodies in the course of Gaucher disease type 1: A multicenter study comparing Gaucher disease patients to healthy subjects. <i>Joint Bone Spine</i> , 2018, 85, 71-77.	0.8	9
57	Stem cell properties of peripheral blood endothelial progenitors are stimulated by soluble CD146 via miR-21: potential use in autologous cell therapy. <i>Scientific Reports</i> , 2018, 8, 9387.	1.6	9
58	Single or triple positivity for antiphospholipid antibodies in "carriers" or symptomatic patients: Untangling the knot. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3018-3030.	1.9	9
59	Restoration of soluble CD146 in patients with Crohn's disease treated with the TNF- α antagonist infliximab. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 1315-1317.	0.9	8
60	Soluble CD146, an innovative and non-invasive biomarker of embryo selection for in vitro fertilization. <i>PLoS ONE</i> , 2017, 12, e0173724.	1.1	8
61	The first assessment of soluble CD146 in women with unexplained pregnancy loss. A new insight?. <i>Thrombosis and Haemostasis</i> , 2005, 94, 1280-4.	1.8	8
62	ICARE improves antinuclear antibody detection by overcoming the barriers preventing accreditation. <i>Clinica Chimica Acta</i> , 2016, 454, 57-61.	0.5	7
63	Quantification of Antifibrillar (anti-U3 RNP) Antibodies: A New Insight for Patients with Systemic Sclerosis. <i>Diagnostics</i> , 2021, 11, 1064.	1.3	6
64	CD146 deficiency promotes plaque formation in a mouse model of atherosclerosis by enhancing RANTES secretion and leukocyte recruitment. <i>Journal of Molecular and Cellular Cardiology</i> , 2019, 130, 76-87.	0.9	5
65	Lung involvement associated with anti-NXP2 autoantibodies in inflammatory myopathies: a French monocenter series. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 845-850.	1.0	5
66	Should we look for anti-RNA polymerase III antibodies in systemic sclerosis patients with anti-centromere or anti-topoisomerase I antibodies?. <i>European Journal of Internal Medicine</i> , 2017, 44, e42-e44.	1.0	4
67	Interest of IgG and IgM antiprothrombin autoantibodies in the exploration of antiphospholipid syndrome: a 5-year retrospective study. <i>Rheumatology</i> , 2020, 59, 1539-1544.	0.9	4
68	Anti-NuMA antibodies: clinical associations and significance in patients with primary Sjögren's syndrome or systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 4074-4084.	0.9	4
69	Multiple variants of soluble CD146 are involved in Systemic Sclerosis: identification of a novel pro-fibrotic factor. <i>Arthritis and Rheumatology</i> , 2022, , .	2.9	4
70	Clinical Evaluation of a New Quantitative Enzyme-Linked Immunosorbent Assay for Detection of Double-Stranded DNA Autoantibodies. <i>Annals of the New York Academy of Sciences</i> , 2007, 1109, 511-518.	1.8	3
71	Biopsy-proven kidney involvement in hypocomplementemic urticarial vasculitis. <i>BMC Nephrology</i> , 2022, 23, 67.	0.8	3
72	Thromboses in tuberculosis are linked to antiphosphatidylethanolamine antibodies levels: A cross-sectional study. <i>Journal of Clinical Tuberculosis and Other Mycobacterial Diseases</i> , 2019, 15, 100092.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Sera From Patients With Minimal Change Disease Increase Endothelial Permeability to Sodium. <i>Kidney International Reports</i> , 2020, 5, 1071-1075.	0.4	2
74	Endothelial-Specific Deletion of CD146 Protects Against Experimental Glomerulonephritis in Mice. <i>Hypertension</i> , 2021, 77, 1260-1272.	1.3	2
75	Soluble CD146 as a Potential Target for Preventing Triple Negative Breast Cancer MDA-MB-231 Cell Growth and Dissemination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 974.	1.8	2
76	Anti-Ephrin Type-B Receptor 2 (EphB2) and Anti-Three Prime Histone mRNA EXonuclease 1 (THEX1) Autoantibodies in Scleroderma and Lupus. <i>PLoS ONE</i> , 2016, 11, e0160283.	1.1	1
77	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 899-900.	2.9	1
78	Considering the level of myositis-specific autoantibodies could improve the precision of multiplex assay : lesson from patients with multiple positive results. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151871.	1.6	1
79	The Role of the Adhesion Receptor CD146 and Its Soluble Form in Human Embryo Implantation and Pregnancy. <i>Frontiers in Immunology</i> , 2021, 12, 711394.	2.2	1
80	Soluble CD146 is increased in preeclampsia and interacts with galectin-1 to regulate trophoblast migration through VEGFR2 receptor. <i>F&S Science</i> , 2022, 3, 84-94.	0.5	1
81	C0412 soluble CD146: A new angiogenic factor involved in physiopathology. <i>Thrombosis Research</i> , 2012, 130, S108.	0.8	0
82	The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine. <i>Journal of Immunological Methods</i> , 2017, 440, 27-34.	0.6	0
83	MCAM and its Isoforms as Novel Targets in Angiogenesis Research and Therapy. , 2017, , .		0
84	Lung involvement associated with anti-NXP2 autoantibodies: a monocentre observational French study. , 2018, , .		0